Latest chemotherapy Stories
Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab THOUSAND OAKS, Calif., Jan.
Findings Published in Journal of Community and Supportive Oncology Are First to Show Improvement in Emotional Well-Being and Quality of Life NEW YORK, Jan.
- Results from two large trials individually showed an improvement in the secondary endpoint of overall survival for patients with the most common EGFR mutation (Del19) RIDGEFIELD, Conn., Jan.
A vitamin regimen aimed at reducing a serious chemotherapy side effect may not work for many mesothelioma patients. Raleigh, NC (PRWEB) January 10, 2015
French researchers say doctors treating mesothelioma patients with pemetrexed should watch out for a potentially-serious but often-unrecognized side effect. Raleigh,
Doctors Ron Benitez and Yaron Moshel are offering their NJ patients ground -breaking treatments not found anywhere else in the state Morristown, NJ (PRWEB)
INDIANAPOLIS, Dec. 26, 2014 /PRNewswire/ -- Jerry Levinson was 45 when he began having difficulty swallowing, developed heartburn and vague chest pains.
Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in Patients with Lower Performance Status Phase
Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...